Biggest Battles in Biopharma

You know the picture: Two pharma CEOs, shaking hands and smiling as cameras flash and video rolls. It's been common enough, especially recently, as Pfizer and Wyeth, Merck and Schering-Plough announced their big mergers.

But that's not always the way M&A goes. While many pharma deals over the past 20 years have been relatively friendly, others haven't. Hostile bids, media grandstanding, warring press releases--unfriendly mergers have triggered them all.

The following list includes some of the biggest battles of the last two decades. We've covered a few of them ourselves, but others are before our time, such as Pfizer's Warner-Lambert takeover. Click below to get all the details on some of the industry's biggest takeover battles.
Click here to get started 

1. Sun Pharma vs. Taro
2. Pfizer vs. Warner-Lambert
3. Aventis vs. Sanofi-Synthelabo
4. Astellas Pharma vs. OSI Pharmaceuticals
5. King Pharmaceuticals vs. Alpharma
6. Novartis vs. Alcon
7. BMS vs. Icahn
8. Genzyme vs. Icahn

Read more on

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

The antidepressant Zoloft and its generics are in short supply as the COVID-19 pandemic has caused higher demand and manufacturing interruptions.

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.